Literature DB >> 12967782

CD4+CD25+ regulatory T cells mediate acquired transplant tolerance.

Soji F Oluwole1, Olakunle O Oluwole, Hector A DePaz, Ayotunde O Adeyeri, Piotr Witkowski, Mark A Hardy.   

Abstract

The Holy Grail of clinical organ transplantation is the safe induction of allograft tolerance. Transplant tolerance has been successfully induced in animal models. Since T cells play a pivotal role in graft rejection, modulating T cell function has been the primary focus of studies aimed at inducing transplant tolerance. Rodent models of transplant tolerance induction include central deletion and peripheral mechanisms involving activation-induced cell death (AICD), anergy, immune deviation, and production of regulatory T cells. These mechanisms are not mutually exclusive. Although clonal deletion and anergy limit self-reactive T cells in the thymus, these mechanisms alone are not sufficient for controlling self-reactive T cells in the periphery. There is now evidence that the adult animal harbors two functionally distinct populations of CD4(+) T cells; one mediates autoimmune disease and the other dominantly inhibits it. The latter cells express CD4, CD25 and CTLA-4. These thymus-derived T cells have recently been shown to mediate the induction and maintenance of transplant tolerance. These CD4(+)CD25(+) T cells are similar in origin, phenotype, and function to those that maintain natural self-tolerance and T cell homeostasis in the periphery. Against this background, is it possible that alloantigen specific regulatory T cells might be generated and expanded ex vivo before organ transplantation and then infused to induce long-term tolerance, perhaps without the need for chronic immunosuppression?

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967782     DOI: 10.1016/S0966-3274(03)00046-7

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

1.  Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.

Authors:  Christian H Poehlein; Daniel P Haley; Edwin B Walker; Bernard A Fox
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

2.  The long road to pancreatic islet transplantation.

Authors:  Mark A Hardy; Piotr Witkowski; Hugo Sondermeijer; Paul Harris
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 3.  Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.